Skip to main content

Table 2 Shows the endpoints reported by each of the included trials

From: Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials

Trials

No of patients (DAPT + TAPT)

Follow up period (month)

Reported endpoints/outcomes

Han 2009 [6]

263

12

MACEs, TVR, and ADR.

Lee 2011 [33]

176

12

MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR.

Lee 2008 [5]

400

9

MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR.

Lee 2007 [34]

166

9

MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR.

Yang 2011 [35]

154

–

PRU and PA

Yang 2007 [36]

55

7

PA

Capranzano 2012 [37]

80

1

PRU and PRI

Angiolillo 2008 [38]

40

1

PRI and PA

Angiolillo 2011 [39]

106

1

PRI

Ha 2013 [40]

84

2

PRU and PA

  1. Abbreviations: MACEs major adverse cardiac effects, TVR target vessel revascularization, TLR target lesion revascularization, BL bleeding, ST stent thrombosis, ADR adverse drug reactions, D death, MI myocardial infarction, PA platelet aggregation, PRI platelet reactivity index, PRU platelet reactivity unit